Patrick J. Heron

Insider Reports History

Entity
Individual
Location
550 Hamilton Ave., Suite 100, Palo Alto, CA
Signature
/s/ Steve R. Bailey, as Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Patrick J. Heron:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Mirum Pharmaceuticals, Inc. Director Common Stock 3.57M $133M $37.40 Sep 18, 2024 By Frazier Life Sciences IX, L.P.
Imago BioSciences, Inc. Director Common Stock 2.31M $83.2M $36.00 Jul 20, 2021 Indirect
Mirum Pharmaceuticals, Inc. Director Common Stock 162K $6.07M $37.40 Sep 18, 2024 By Frazier Life Sciences X, L.P.
Arcutis Biotherapeutics, Inc. Director, 10%+ Owner Common Stock 18.8K $151K $8.01 Jun 14, 2024 Direct
Mirum Pharmaceuticals, Inc. Director Restricted Stock Units 5.7K $146K $25.68 Jun 5, 2024 Direct
MBX Biosciences, Inc. Director, 10%+ Owner Common Stock 4.55M Sep 16, 2024 By Frazier Life Sciences X, L.P.
Arcutis Biotherapeutics, Inc. Director, 10%+ Owner Stock Option (right to buy) 27.1K Jun 14, 2024 Direct
Imago BioSciences, Inc. Director Stock Option (Right to Buy) 23.8K Jul 15, 2021 Direct
HilleVax, Inc. Director, 10%+ Owner Stock Option 22.5K Jun 7, 2023 Direct
MBX Biosciences, Inc. Director, 10%+ Owner Stock Option (Right to Buy) 16K Sep 12, 2024 Direct
Vaxcyte, Inc. Director Stock Option (right to buy) 15K Jun 2, 2021 Direct
Mirum Pharmaceuticals, Inc. Director Stock Option (right to buy) 8.78K Jun 5, 2024 Direct
Imago BioSciences, Inc. Director Series A Preferred Stock 0 Jul 20, 2021 Indirect
Imago BioSciences, Inc. Director Series B Preferred Stock 0 Jul 20, 2021 Indirect
Imago BioSciences, Inc. Director Series C Preferred Stock 0 Jul 20, 2021 Indirect
MBX Biosciences, Inc. Director, 10%+ Owner Series A Convertible Preferred Stock 0 Sep 16, 2024 By Frazier Life Sciences X, L.P.
MBX Biosciences, Inc. Director, 10%+ Owner Series B Convertible Preferred Stock 0 Sep 16, 2024 By Frazier Life Sciences X, L.P.

Insider Reports Filed by Patrick J. Heron

Symbol Company Period Transactions Value $ Form Type Date Filed Role
MIRM Mirum Pharmaceuticals, Inc. Sep 18, 2024 1 $4.3K 4 Sep 20, 2024 Director
MBX MBX Biosciences, Inc. Sep 16, 2024 4 $10M 4 Sep 17, 2024 Director, 10%+ Owner
MBX MBX Biosciences, Inc. Sep 12, 2024 1 $0 4 Sep 13, 2024 Director, 10%+ Owner
MBX MBX Biosciences, Inc. Sep 12, 2024 0 $0 3 Sep 12, 2024 Director, 10%+ Owner
MIRM Mirum Pharmaceuticals, Inc. Sep 6, 2024 1 $9.56K 4 Sep 10, 2024 Director
ARQT Arcutis Biotherapeutics, Inc. Jun 14, 2024 2 $0 4 Jun 18, 2024 Director, 10%+ Owner
MIRM Mirum Pharmaceuticals, Inc. Jun 5, 2024 2 $0 4 Jun 7, 2024 Director
ARQT Arcutis Biotherapeutics, Inc. Mar 4, 2024 1 $200K 4 Mar 6, 2024 Director
MIRM Mirum Pharmaceuticals, Inc. Nov 9, 2023 1 $82.4K 4 Nov 14, 2023 Director
MIRM Mirum Pharmaceuticals, Inc. Sep 13, 2023 1 $81.4K 4 Sep 15, 2023 Director
MIRM Mirum Pharmaceuticals, Inc. Sep 11, 2023 2 $257K 4 Sep 13, 2023 Director
MIRM Mirum Pharmaceuticals, Inc. Aug 31, 2023 1 $3.88M 4 Sep 5, 2023 Director, 10%+ Owner
MIRM Mirum Pharmaceuticals, Inc. Jun 12, 2023 1 $0 4 Jun 14, 2023 Director, 10%+ Owner
HLVX HilleVax, Inc. Jun 7, 2023 1 $0 4 Jun 9, 2023 Director, 10%+ Owner
ARQT Arcutis Biotherapeutics, Inc. May 31, 2023 2 $0 4 Jun 2, 2023 Director, 10%+ Owner
HLVX HilleVax, Inc. Aug 19, 2022 1 $0 4 Aug 23, 2022 Director, 10%+ Owner
MIRM Mirum Pharmaceuticals, Inc. Jun 2, 2022 1 $0 4 Jun 6, 2022 Director, 10%+ Owner
ARQT Arcutis Biotherapeutics, Inc. Jun 1, 2022 2 $0 4 Jun 3, 2022 Director, 10%+ Owner
IMGO Imago BioSciences, Inc. Jul 20, 2021 14 $3M 4 Jul 20, 2021 Director
IMGO Imago BioSciences, Inc. Jul 15, 2021 1 $0 4 Jul 19, 2021 Director
IMGO Imago BioSciences, Inc. Jul 15, 2021 0 $0 3 Jul 15, 2021 Director
ARQT Arcutis Biotherapeutics, Inc. Jun 9, 2021 1 $0 4 Jun 11, 2021 Director, 10%+ Owner
MIRM Mirum Pharmaceuticals, Inc. Jun 4, 2021 1 $0 4 Jun 8, 2021 Director, 10%+ Owner
PCVX Vaxcyte, Inc. Jun 2, 2021 1 $0 4 Jun 3, 2021 Director